Media & Resources

Despite downward revision on HIV/AIDS prevalence data, epidemic requires a vaccine.

Study of Merck vaccine candidate is stopped in South Africa; trial is unblinded.

The International AIDS Vaccine Initiative Applauds the Governments of India, the United Kingdom, and South Africa for their Commitment to Exploring New Financial Incentives to Accelerate AIDS Vaccine R&D.

Though the outcome is disappointing, IAVI urges the field to maintain hope and embrace innovation.

TOKYO & NEW YORK, September 20, 2007—The International AIDS Vaccine Initiative (IAVI), a global organization working to speed the development of preventive AIDS vaccines, will collaborate on the development of a novel AIDS vaccine technology with University of Tokyo faculty member Tetsuro Matano, IAVI announced today. Professor Matano, MD, PhD, will act as a scientific…

As the AIDS vaccine field moves toward larger-scale efficacy trials, investigators’ findings could reshape enrollment in developing nations.

New class of viral vector tapped to target primary site of HIV replication; Agreement marks IAVI’s first product development partnership with Japanese company.

On August 8, South African President Thabo Mbeki dismissed his Deputy Health Minister, Nozizwe Madlala-Routledge, a well-respected figure in the international HIV/AIDS world. In a letter to Madlala-Routledge explaining his decision, Mbeki complained that the deputy minister had traveled to Madrid in June on official business without his approval.  She traveled to Madrid, to attend…